I'm debating about contacting the DOJ and letting them know that I personally didn't base my decision about buying shares on the fact that Nader stated a complete BLA was submitted, but instead on the years and years of success it has had with its HIV trials saving & improving the quality of lives, being administered to someone I know during Covid and saving that person's life (with additional side benefits), all the success it had during the compassionate use approvals with Covid, the fact that it had a tremendous success rate with the older population during it's Covid trial but that the FDA wouldn't look at it, the survival rates it had shown in the basket trial, and the fact that it is one of the best immune system modulators I have ever come across that has applications from HIV to Nash to breast cancer to Alzheimer's to just about you name it.

They will probably hang up on me but I honestly feel like I should do that... thoughts? Last time retail investors contacted a government agency on behalf of the company, it backfired...with a FDA bash letter.

Also, when the DOJ says victims, do they mean those who were denied Leronlimab when they needed it the most but are now dead?

DOJ/SEC going after the big crime syndicates here...talk about resources (our taxes) spent wisely...

As for silence is golden - The clinical hold lift in mid-Jan along w/ a rebranding alongside that would be all the noise I need to hear - the proverbial Leronlimab shot heard round the world.

Sorry...had to let off a little steam.